| 词条 | Eisai (company) |
| 释义 |
|name = Eisai Co., Ltd. |native_name = エーザイ株式会社 |native_name_lang = ja |logo = Eisai logo.svg |logo_size = 200px |type = Public (K.K) |traded_as = {{TYO|4523}} TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component |founder = Toyoji Naito |foundation = {{Start date and age|1941|12|06}} |location = 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan |key_people = Haruo Naito (President and CEO) |industry = Pharmaceuticals |products = {{unbulleted list| Lenvema| Halaven| Aricept|Pariet|Banzel|Zonegran|Fycompa|Zebinix}} |revenue = {{increase}} US$ 5.82 billion (FY 2013) JPY 600.4 billion (FY 2013) |net_income = {{increase}} US$ 320 million (FY 2013) JPY 33 billion (FY 2013) |num_employees = 10,419 (consolidated, as of March 31, 2014) |homepage = {{Official website|http://www.eisai.com/index.html}} |footnotes = [1] }}{{nihongo|Eisai Co., Ltd.|エーザイ株式会社|Ēzai Kabushiki-gaisha|lead=yes}} is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[2] HistoryNihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[3] The American subsidiary of the company, Eisai Inc., was established in 1995.[4] In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson. In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals. In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases. In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for $3.9 billion USD. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio. In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel.[5] LocationsEisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary Eisai Inc. is headquartered in Woodcliff Lake, New Jersey. Eisai maintains medical research headquarters in Woodcliff Lake, New Jersey as well as locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Andover Innovative Medicines Institute are based.[6][7] The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region. ProductsSome of the key products that Eisai produces or markets with partners include:
AriceptAricept accounted for 40% of Eisai's revenue as of March 2010.[8] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[8] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[8] See also{{Portal bar|Japan|Medicine|Companies}}
References1. ^{{cite web |url=http://www.eisai.com/company/profile/index.html |title=Corporate Information |publisher=Eisai Co., Ltd. |accessdate=February 9, 2015}}{{self-published inline|certain=y|date=March 2015}} 2. ^{{cite web |url=http://indexes.nikkei.co.jp/en/nkave/index/component?idx=nk225#09 |title=Components:Nikkei Stock Average |publisher=Nihon Keizai Shimbun |accessdate=February 9, 2015}} 3. ^{{cite encyclopedia |first=Claudia |last=Winograd |editor-last=Colditz |editor-first=Graham A. |title=Eisai (Japan) | encyclopedia=Encyclopedia of Cancer and Society |date=October 16, 2007 |publisher=Sage Publications |url=http://www.sageknowledge.org/view/cancer/n204.xml |doi=10.4135/9781412953979 |isbn=9781412949897 |accessdate=February 9, 2015 }} 4. ^{{cite web |url=http://www.businesswire.com/news/home/20100618005322/en/Lonnel-Coats-Appointed-President-Chief-Executive-Officer#.VNik5S5vW4A |title=Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc. |publisher=Businesswire |accessdate=February 9, 2015}} 5. ^{{cite news |url=http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archiveurl=https://web.archive.org/web/20150209123421/http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archivedate=February 9, 2015 |title=NORD to Honor Rare Disease Pioneers |publisher=PR Newswire |date=May 11, 2009 |accessdate=February 9, 2015}} 6. ^{{Cite news|url=https://endpts.com/eisai-launches-research-division-in-massachusetts-aimed-at-alzheimers-io-and-autoimmune-diseases/|title=Eisai launches biotech division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases|last=Carroll|first=John|date=15 September 2016|work=Endpoint News|access-date=4 November 2016}} 7. ^{{Cite news|url=|title=Eisai Launches Facility to Advance Precision Medicine|last=|first=|date=15 October 2016|work=Genetic Engineering & Biotechnology News|department=News: Industry Watch|page=8|type=Paper}} 8. ^1 2 {{cite news |title=Eisai Aricept Patch for Alzheimer’s Isn’t Ready for Approval |author=Kanoko Matsuyama |agency=Bloomberg L.P. |date=April 25, 2011 |accessdate=April 25, 2011 |url=https://www.bloomberg.com/news/2011-04-25/eisai-says-fda-indicates-aricept-nda-not-ready-for-approval.html }} External links
6 : Life sciences industry|Pharmaceutical companies based in Tokyo|Companies listed on the Tokyo Stock Exchange|Pharmaceutical companies established in 1941|1941 establishments in Japan|Japanese brands |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。